Evaluation of in vitro production of IFN-γ, IL-10, IL-12 and IL-13 by blood cells in patients with cutaneous leishmaniasis lesions

Iranian Journal of Allergy, Asthma and Immunology

Volumn 4, Issue 1, 2005, Pages 15-21

  Mahmoodi, Majid ^a,b   Rajabalian, Saeid ^a   Fekri, Alireza ^a   Esfandiarpour, Iraj ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Interferon gamma; Interleukin 11; Interleukin 12; Interleukin 13; Interleukin 5; Leishmania tropica; Leishmaniasis

Indexed keywords

EID: 60349085513     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14 (5):417-23.
2. Khamesipour A, Dowlati Y, Asilian A, Hashemi- Fesharki R, Javadi A, Noazin S, et al. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005; 23 (28):3642-8.
3. Sacks DL, Kenney RT, Kreutzer RD, Jaffe CL, Gupta AK, Sharma MC, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345 (8955):959-61.
4. Javadian E, Nadim A, Tahvildare-Bidruni G, Assefi V. Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan Part V: Report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bull Soc Pathol Exot Filiales 1976; 69 (2):140-3.
5. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol. 1996; 14 (5):425-31.
6. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
7. Etges R, Muller I. Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions. J Mol Med 1998; 76 (6):372-90.
8. Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis 1991; 13 (5):1009-17.
9. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177 (5):1505-9.
10. Nacy CA, Meltzer MS. T-cell-mediated activation of macrophages. Curr Opin Immunol 1991; 3 (3):330-5.
11. Louzir H, Melby PC, Ben Salah A, Marrakchi H, Aoun K, Ben Ismail R, et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 1998; 177 (6):1687-95.
12. Coutinho SG, Oliveira MP, Da-Cruz AM, DeLuca PM, Mendonca SC, Bertho AL, et al. T- cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol 1996; 84:144-55.
13. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 2003; 170 (10):5152-8.
14. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie ANJ. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000; 164 (3):1458-62.
15. Launois, P., Tacchini-Cottier, F., Parra-Lopez, C. and Louis, J.A. Cytokines in parasitic diseases: the example of cutaneous leishmaniasis. Int Rev Immunol 1998; 17:157-80.
16. Kurtzhals JA, Kemp M, Poulsen LK, Hansen MB, Kharazmi A, Theander TG. Interleukin-4 and interferon-gamma production by Leishmania stimulated peripheral blood mononuclear cells from nonexposed individuals. Scand J Immunol 1995; 41 (4):343-9.
17. Takegoshi K, Ogai H, Sugimoto T, Ohmoto Y. Production of IFN-γ and IL-12 by peripheral whole blood is maintained in hepatitis C virus patients with persistently normal alanine transferase activity: A preliminary report. Hepatol Res. 2004; 29 (2):81-8.
18. Matalka KZ. Prolactin enhances production of interferon-gamma, interleukin-12, and interleukin-10, but not of tumor necrosis factor-alpha, in a stimulusspecific manner. Cytokine. 2003; 21 (4):187-94.
19. Kallio R, Surcel HM, Syrjala H. Peripheral mononuclear cell IL-10 and IL-12 production is not impaired in patients with advanced cancer and severe infection. Cytokine 2002; 20 (5):210-4.
20. Wilczynski JR, Tchorzewski H, Banasik M, Glowacka E, Wieczorek A, Lewkowicz P, Malinowski A, Szpakowski M, Wilczynski J. Lymphocyte subset distribution and cytokine secretion in third trimester decidua in normal pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol 2003; 109 (1):8-15.
21. Habibi GR, Khamesipour A, McMaster WR, Mahboudi F. Cytokine gene expression in healing and nonhealing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol 2001; 54 (4):414-20.
22. Ritter U, Korner H. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunol 2002; 24 (6):295-301.
23. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166 (2):1141-7.
24. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol. 1995; 154 (10):5320-30.
25. Alexander J, Brombacher F, McGachy HA, McKenzie AN, Walker W, Carter KC. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur J Immunol 2002; 32 (10):2923-33.
26. Bourreau E, Revot G, Pradinaud R, Launois P. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous Leishmaniasis lesions and renders specific CD4 T cells unresponsive to IL-12. J Infect Dis 2001; 183 (6):953-9.
27. Bosque F, Saravia NG, Valderrama L, Milon G. Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand J Immunol. 2000; 51 (5):533-41.